Emerging Treatments for Alzheimer's Disease
DOI:
https://doi.org/10.54097/hset.v54i.9778Keywords:
Alzheimer’s Disease, Emerging treatment.Abstract
The treatment of Alzheimer's disease (AD), a complex neurodegenerative disorder, presents significant challenges. At the same time, addressing these challenges is essential for enhancing patient outcomes. In this paper, pharmacological and non-pharmacological treatments for AD in both current and emerging size are discussed. It discusses the implications of these treatments for AD patients and their families, as well as the potential societal impact of improved treatment. In addition, the author highlights challenges and opportunities in clinical trial design, regulatory and ethical considerations for emerging treatments, future directions for the treatment of AD, as well as the role of public health policies and research funding. Personalized medicine and combination therapies are indicating possible directions for the future of AD treatment. However, there are still challenges, such as the design of clinical trials, regulatory and ethical considerations, public health policies, and funding for research. Improvements in care and outcomes for people with AD still need some concerted efforts from healthcare providers, researchers, policymakers, and advocates.
Downloads
References
Hung CW, Chen YC, Hsieh WL, Chiou SH, Kao CL. Ageing and neurodegenerative diseases. Ageing Res Rev, 2010, 9: S36 - 46.
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2011 Mar; 7.
Alzheimer's Association. About Alzheimer's disease: Alzheimer's basics. https://www.alz.org/alzheimer-s-dementia/what-is-alzheimer-s.
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., & Tariot, P. N. Trial of solanezumab for mild dementia due to Alzheimer's disease. New England Journal of Medicine, 2018, 378 (4), 321 - 330.
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., & Canete, P. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 2016, 537 (7618), 50 - 56.
Wisniewski, T., & Drummond, E. Developing treatments for Alzheimer's disease: progress and challenges. Nature Medicine, 2016, 22 (3), 312 - 322.
Zhao, Y., Cong, L., Lukiw, W. J., & Bickford, P. C. Oxidative stress-related mechanisms and antioxidants in Alzheimer's disease: a systematic review. Nutrients, 2020, 12 (7), 2009.
Janson J, Laedtke T, Parisi JE, O'Brien PC, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2021, 70 (1): 109 - 115.
Tanzi RE. Genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2020, 10 (2): a036796.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011, 377 (9770): 1019 - 1031.
Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14 (4): 388 - 405.
Jomova K, Vondra ova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010, 345 (1-2): 91 - 104.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018, 14 (4): 535 - 562.
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016, 15 (7): 673 - 684.
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev.
Reisberg B, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med.
National Institute on Aging. Alzheimer's Disease & Related Dementias. Available at: https://www.nia.nih.gov/health/alzheimers.
Spector A, et al. Cognitive stimulation for the treatment of Alzheimer's disease. Cochrane Database Syst Rev.
Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 2011, 286 (13): 10457 - 10461.
Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010, 9 (5): 387 - 398.
Minter MR, Taylor JM, Crack PJ. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. J Neurochem. 2016, 136 (3): 457 - 474.
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14 (4): 388 - 405.
Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis. 2018, 62 (3): 1403 - 1416.
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020, 6 (1): e12050.
de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci. 2010, 1207: 46 - 56.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020, 396 (10248): 413 - 446.
Grill JD, Raman R, Ernstrom K, et al. The Third Revolution in Alzheimer Research: Targeting the Brain. J Alzheimers Dis. 2021, 80 (4): 1349 - 1370.
U.S. Food and Drug Administration. Expedited Programs for Serious Conditions - Drugs and Biologics. Accessed on March 16, 2023.
World Health Organization. Ethical considerations for health policy and systems research. Available at: Accessed on March 16, 2023.
Bredesen DE. Reversal of cognitive decline: A novel therapeutic program. Aging (Albany NY). 2014, 6 (9): 707 - 717.
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical Trials and Late-Stage Drug Development for Alzheimer's Disease: An Appraisal from 1984 to 2014. J Intern Med. 2014, 275 (3): 251 - 283.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
